Drammen Sykehus

Running trials

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· Source

• Active, not recruiting

  Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

  NCT07220642· Phase 3· Source

• Recruiting

  Antiplatelet therapy added to standard thromboprophylaxis to prevent thrombosis in pancreatic cancer patients - a randomized clinical trial (The PANART trial)

  2023-509022-22-00· Phase 3· Source

• Recruiting

  Thrombolysis in Factor Xa-inhibitors Trial

  NCT06878066· Phase 3· Source

• Active, not recruiting

  Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcutaneous TNF inhibitor: The Rheumatoid Arthritis therapeutic DRUg Monitoring trial (RA-DRUM)

  2023-510184-35-00· Phase 4· Source

• Recruiting

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Source

• Recruiting

  SACK

  2022-501600-10-00· Phase 3· Source

• Recruiting

  Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress

  NCT03968393· Phase 4· Source

• Active, not recruiting

  An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS

  2023-507906-15-00· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation3 recruiting
• Chronic kidney disease2 recruiting
• Stroke2 recruiting
• Metastatic breast cancer1 recruiting
• Pancreatic cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  The TAF-MS study

  2023-503814-62-00· Phase 2· Source

• Active, not recruiting

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· Phase 3· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Source